Home > Press Releases

Press Releases (Page 7)

Sharps Compliance Reschedules Third Quarter Fiscal 2022 Conference Call and Webcast

HOUSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Sharps Compliance Corp. (NASDAQ: SMED) announced today that it has rescheduled the release of its third quarter 2022 financial results. The Company will release third quarter 2022 results for the period ended March 31, 2022, before the opening of the financial markets on Thursday, May 12, 2022. A conference call and webcast will follow at 11:00 a.m. ET, in which management will discuss the... ❯❯❯

Amedisys Names Nick Muscato as Chief Strategy Officer

BATON ROUGE, La., April 26, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care, announces the promotion of Nick Muscato to Chief Strategy Officer, effective immediately. “I am thrilled to announce the promotion of Nick Muscato to Chief Strategy Officer,” stated Chris Gerard, President and CEO of Amedisys. “He brings a wealth of expertise to the... ❯❯❯

Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022

SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2022, after the market close on Wednesday, May 11, 2022. Ron Rocca, Exagen’s President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the... ❯❯❯

OnKure Therapeutics Expands Boulder Footprint with the Opening of a New Research Laboratory

BOULDER, Colo., April 25, 2022 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today announced that the Company is expanding its operations with the opening of a research laboratory in Boulder, Colorado. The state-of-the-art facility has been designed to support the chemical synthesis and biological assays needed to identify... ❯❯❯

Ramsay Sante : positive outcome of the recommended public offer to acquire GHP Specialty Care

Press releaseParis, 25 April, 2022 Positive outcome of the recommended public offer to acquire GHP Specialty Care On March 7, 2022, Ramsay Santé, through its Swedish subsidiary Capio Group Services AB (“Capio”), has announced a recommended public offer to acquire GHP Specialty Care AB (“GHP”), a Swedish specialty healthcare provider listed on Nasdaq Stockholm. Following the end of the initial acceptance period of the offer,... ❯❯❯

Press release Biocartis Group NV: Biocartis Announces Presentation of Three Idylla™ Studies at 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)

PRESS RELEASE: 25 April 2022, 07:00 CEST Biocartis Announces Presentation of Three Idylla™ Studies at 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Mechelen, Belgium, 25 April 2022 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that three Idylla™ study posters, of which two on the... ❯❯❯

Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Cambridge, MA U.S.A. (April 22, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced that on April 20, 2022, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”)... ❯❯❯

MEDIROM Healthcare Technologies Inc. Regains Compliance with Nasdaq Listing Standard

NEW YORK, April 22, 2022 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the “Company”), announced today that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) on April 19, 2022 informing the Company that it has regained compliance with the minimum market value of listed securities standard under Nasdaq Listing Rule 5550(b)(2) for... ❯❯❯

Press release Biocartis Group NV: Biocartis Reports Results of First Quarter of 2022: On Track to Deliver on Full-Year Guidance, Gross Margin on Products of 35%

PRESS RELEASE: REGULATED INFORMATION 21 April 2022, 07:00 CEST Biocartis Reports Results of First Quarter of 2022: On Track to Deliver on Full-Year Guidance, Gross Margin on Products of 35% Mechelen, Belgium, 21 April 2022 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today provides a business update for the first quarter of 2022 and the outlook... ❯❯❯

Press news Biocartis Group NV: Biocartis Announces Presentation of First Prospective Validation Study Data of Merlin Test by Partner SkylineDx at EADO 2022 Conference

PRESS RELEASE: 21 April 2022, 07:01 CEST Biocartis Announces Presentation of First Prospective Validation Study Data of Merlin Test by Partner SkylineDx at EADO 2022 Conference Mechelen, Belgium, 21 April 2022 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced that its partner SkylineDx will present new data showing that its Merlin Test... ❯❯❯